• Schizophrenia.
• Adjunctive treatment of major depressive disorder.
• Agitation associated with dementia due to Alzheimer’s disease.

Contraindicated in:

• Hypersensitivity.

Use Cautiously in:

• History of seizures or concurrent use of medications that may ↓ seizure threshold
• Pre-existing cardiovascular disease, dehydration, hypotension, concurrent antihypertensives, diuretics, electrolyte imbalance (↑ risk of orthostatic hypotension, correct deficits before treatment)
• Pre-existing low WBC (may ↑ risk of leukopenia/neutropenia
• History of diabetes, metabolic syndrome or dyslipidemia (may exacerbate)
• Patients <24 yr (may ↑ suicidal ideation/behaviors, monitor carefully)
• Patients at risk for falls
• Poor CYP2D6 metabolizers (PM), dose ↓ required
• OB: Use during third trimester may result in extrapyramidal/withdrawal symptoms in infant; use during pregnancy only if potential maternal benefit justifies potential fetal risk
• Lactation: Safety not established during breastfeeding
• Pedi: Antidepressants may ↑ risk of suicidal ideation/behaviors in children; safety and effectiveness not established in children <18 yr (major depressive disorder) or <13 yr (schizophrenia)
• Geri: Appears on Beers list. ↑ risk of stroke, cognitive decline, and mortality in older adults with dementia. Avoid use in older adults, except for schizophrenia, adjunctive treatment of major depressive disorder, or agitation associated with dementia due to Alzheimer's disease.

CV: cerebrovascular adverse reactions (↑ in elderly patients with dementia-related psychoses), orthostatic hypotension/syncope.

EENT: blurred vision.

Endo: hyperglycemia/diabetes.

GI: abdominal pain, constipation, diarrhea, dry mouth, dysphagia, excess salivation, flatulence.

Hemat: agranulocytosis, leukopenia, neutropenia.

Metab: ↑ weight, ↑ appetite, dyslipidemia.

Neuro: akathisia, abnormal dreams, dizziness, drowsiness, dystonia, extrapyramidal symptoms, headache, NEUROLEPTIC MALIGNANT SYNDROME, restlessness, SEIZURES, tardive dyskinesia, tremor, urges (eating, gambling, sexual, shopping).

Misc: body temperature dysregulation, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS).

Drug-Drug:

• Strong CYP3A4 inhibitors, including clarithromycin, itraconazole or ketoconazole, may ↑ levels and risk of toxicity; ↓ brexpiprazole dose.
• Strong CYP2D6 inhibitors, including fluoxetine, paroxetine, or quinidine may ↑ levels and risk of toxicity; ↓ brexpiprazole dose.
• Combined use of strong or moderate CYP3A4 inhibitors with strong or moderate CYP2D6 inhibitors in addition to brexpiprazole including the following combinations itraconazole + quinidine, fluconazole + paroxetine, itraconazole + duloxetine or fluconazole + duloxetine may ↑ levels and risk of toxicity; ↓ brexpiprazole dose.
• Strong CYP3A4 inducers, including rifampin, may ↓ levels and effectiveness; ↑ brexpiprazole dose.
• Concurrent use of antihypertensives or diuretics may ↑ the risk of hypotension.
• Concurrent use of medications that may ↓ seizure threshold may ↑ the risk of seizures.

Drug-Natural Products:

• St. John's wort may ↓ levels and effectiveness; ↑ brexpiprazole dose.

(Generic available)

• Tablets: 0.25 mg; 0.5 mg; 1 mg; 2 mg; 3 mg; 4 mg;

Schizophrenia

• PO (Adults): 1 mg once daily on Days 1–4, then ↑ to 2 mg once daily on Days 5–7, then ↑ to 4 mg once daily on Day 8 (not to exceed 4 mg once daily). Known CYP2D6 poor metabolizers: use 50% of the usual dose. Concurrent use of strong CYP2D6 inhibitors (schizophrenia only) or CYP3A4 inhibitors: use 50% of the usual dose; Concurrent use of strong/moderate CYP2D6 inhibitors AND strong/moderate CYP3A4 inhibitors: use 25% of the usual dose; Known CYP2D6 poor metabolizer taking concurrent strong/moderate CYP3A4 inhibitors: use 25% of the usual dose; Concurrent use of strong CYP3A4 inducers: double usual dose over 1–2 wk; titrate by clinical response.
• PO (Children 13–17 yr): 0.5 mg once daily on Days 1–4, then ↑ to 1 mg once daily on Days 5–7, then ↑ to 2 mg once daily on Day 8. May ↑ dose by 1 mg/day on weekly basis (not to exceed 4 mg once daily). Known CYP2D6 poor metabolizers: use 50% of the usual dose. Concurrent use of strong CYP2D6 inhibitors (schizophrenia only) or CYP3A4 inhibitors: use 50% of the usual dose; Concurrent use of strong/moderate CYP2D6 inhibitors AND strong/moderate CYP3A4 inhibitors: use 25% of the usual dose; Known CYP2D6 poor metabolizer taking concurrent strong/moderate CYP3A4 inhibitors: use 25% of the usual dose; Concurrent use of strong CYP3A4 inducers: double usual dose over 1–2 wk; titrate by clinical response.

Major Depressive Disorder

• PO (Adults): 0.5 or 1 mg once daily initially, may be ↑ to 2 mg once daily (not to exceed 3 mg once daily); Known CYP2D6 poor metabolizers: use 50% of the usual dose. Concurrent use of strong CYP2D6 inhibitors (schizophrenia only) or CYP3A4 inhibitors: use 50% of the usual dose; Concurrent use of strong/moderate CYP2D6 inhibitors AND strong/moderate CYP3A4 inhibitors: use 25% of the usual dose; Known CYP2D6 poor metabolizer taking concurrent strong/moderate CYP3A4 inhibitors: use 25% of the usual dose; Concurrent use of strong CYP3A4 inducers: double usual dose over 1–2 wk; titrate by clinical response.

Agitation Associated with Dementia Due to Alzheimer’s Disease

• PO (Adults): 0.5 mg once daily on Days 1–7, then ↑ to 1 mg once daily on Days 8–14, then ↑ to 2 mg once daily on Day 15. May ↑ to 3 mg once daily after ≥14 days based on clinical response and tolerability. Known CYP2D6 poor metabolizers: use 50% of the usual dose. Concurrent use of strong CYP2D6 inhibitors (schizophrenia only) or CYP3A4 inhibitors: use 50% of the usual dose; Concurrent use of strong/moderate CYP2D6 inhibitors AND strong/moderate CYP3A4 inhibitors: use 25% of the usual dose; Known CYP2D6 poor metabolizer taking concurrent strong/moderate CYP3A4 inhibitors: use 25% of the usual dose; Concurrent use of strong CYP3A4 inducers: double usual dose over 1–2 wk; titrate by clinical response.

Rexulti

• Psychotropic activity may be due to partial agonist activity at dopamine D₂ and serotonin 5-HT_1A receptors and antagonist activity at the 5-HT_2A receptor.

• Decreased manifestations of schizophrenia including excitable, paranoic, or withdrawn behavior.
• Improvement in symptoms of depression with increased sense of wellbeing.
• Decreased agitation associated with dementia due to Alzheimer's disease.

Therapeutic Classification: antipsychotics, antidepressants

Pharmacologic Classification: serotonin-dopamine activity modulators (SDAM)

Absorption: Well absorbed (95%) following oral administration.

Distribution: Displays extravascular distribution.

Protein Binding: >99%.

Metabolism/Excretion: Primarily metabolized by the liver via the CYP3A4 and CYP2D6 isoenzymes; the CYP2D6 enzyme system exhibits genetic polymorphism (7% of population may be poor metabolizers and may have significantly ↑ brexpiprazole concentrations and an ↑ risk of adverse effects). 25% excreted in urine (<1% unchanged), 46% in feces (14% unchanged).

Half-life: 91 hr.

(improvement in symptoms)

• Advise patient to take medication as directed and not to skip doses or double up on missed doses. Take missed doses as soon as remembered unless almost time for the next dose. Do not stop taking brexpiprazole without consulting health care professional. Advise patient to read Medication Guide before starting and with each Rx refill in case of changes.
• Inform patient of possibility of extrapyramidal symptoms and tardive dyskinesia. Instruct patient to report these symptoms immediately.
• Advise patient to make position changes slowly to minimize orthostatic hypotension. Protect from falls.
• Medication may cause drowsiness and lightheadedness. Caution patient to avoid driving or other activities requiring alertness until response to medication is known.
• Advise patient and family to notify health care professional if thoughts about suicide or dying, attempts to commit suicide; new or worse depression; new or worse anxiety; feeling very agitated or restless; panic attacks; trouble sleeping; new or worse irritability; acting aggressive; being angry or violent; acting on dangerous impulses; an extreme increase in activity and talking; other unusual changes in behavior or mood occur or if signs and symptoms of high blood sugar (feel very thirsty, urinating more than usual, feel very hungry, feel weak or tired, nausea, confusion, breath smells fruity) occur.
• Inform patient that brexipiprazole may cause weight gain. Advise patient to monitor weight periodically. Notify health care professional of significant weight gain.
• Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult health care professional before taking any new medications. Caution patient to avoid taking alcohol or other CNS depressants concurrently with this medication.
• Advise patient that extremes in temperature should be avoided, because this drug impairs body temperature regulation.
• Advise patient to notify health care professional if new or increased eating/binge eating, gambling, sexual, shopping, or other impulse control disorders occur.
• Advise patient to notify health care professional of medication regimen prior to treatment or surgery.
• Rep: May cause fetal harm. Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected and to avoid breast feeding during therapy. May cause extrapyramidal and/or withdrawal symptoms (agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress feeding disorder) in neonates whose mothers were exposed to antipsychotic drugs during third trimester of pregnancy. Symptoms vary in severity. Some neonates recover within hrs or days without specific treatment; others required prolonged hospitalization. Monitor neonates for extrapyramidal and/or withdrawal symptoms and manage symptoms appropriately. Encourage pregnant patients to enroll in registry by contacting National Pregnancy Registry for Atypical Antipsychotics at 1-866-961-2388 or visit womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/.
• Emphasize the importance of routine follow-up exams and continued participation in psychotherapy as indicated.

brex-PIP-ra-zole

NDC Code^*

• 59148- Otsuka America Pharmaceutical, Inc.
  • 59148-035- REXULTI
    • 59148-035-13- 30 TABLET in 1 BOTTLE (59148-035-13)

• 59148- Otsuka America Pharmaceutical, Inc.
  • 59148-036- REXULTI
    • 59148-036-13- 30 TABLET in 1 BOTTLE (59148-036-13)

• 59148- Otsuka America Pharmaceutical, Inc.
  • 59148-037- REXULTI
    • 59148-037-13- 30 TABLET in 1 BOTTLE (59148-037-13)

• 59148- Otsuka America Pharmaceutical, Inc.
  • 59148-038- REXULTI
    • 59148-038-13- 30 TABLET in 1 BOTTLE (59148-038-13)

• 59148- Otsuka America Pharmaceutical, Inc.
  • 59148-039- REXULTI
    • 59148-039-13- 30 TABLET in 1 BOTTLE (59148-039-13)

• 59148- Otsuka America Pharmaceutical, Inc.
  • 59148-040- REXULTI
    • 59148-040-13- 30 TABLET in 1 BOTTLE (59148-040-13)